PubMed:32907635 / 4245-5081 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T15","span":{"begin":77,"end":81},"obj":"Body_part"},{"id":"T16","span":{"begin":224,"end":235},"obj":"Body_part"},{"id":"T17","span":{"begin":254,"end":258},"obj":"Body_part"}],"attributes":[{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma50723"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma7182"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma50723"}],"text":"SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T11","span":{"begin":72,"end":81},"obj":"Body_part"},{"id":"T12","span":{"begin":77,"end":81},"obj":"Body_part"},{"id":"T13","span":{"begin":254,"end":258},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0035552"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0001638"}],"text":"SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T30","span":{"begin":82,"end":92},"obj":"Disease"},{"id":"T31","span":{"begin":126,"end":144},"obj":"Disease"},{"id":"T32","span":{"begin":146,"end":167},"obj":"Disease"},{"id":"T33","span":{"begin":168,"end":179},"obj":"Disease"},{"id":"T34","span":{"begin":190,"end":198},"obj":"Disease"},{"id":"T35","span":{"begin":259,"end":269},"obj":"Disease"},{"id":"T36","span":{"begin":283,"end":289},"obj":"Disease"},{"id":"T38","span":{"begin":708,"end":746},"obj":"Disease"}],"attributes":[{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005279"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005068"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0004496"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0005053"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A37","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0001243"}],"text":"SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T37","span":{"begin":24,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T38","span":{"begin":77,"end":81},"obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"T39","span":{"begin":77,"end":81},"obj":"http://www.ebi.ac.uk/efo/EFO_0000816"},{"id":"T40","span":{"begin":181,"end":189},"obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"T41","span":{"begin":181,"end":189},"obj":"http://www.ebi.ac.uk/efo/EFO_0000814"},{"id":"T42","span":{"begin":224,"end":235},"obj":"http://www.ebi.ac.uk/efo/EFO_0000876"},{"id":"T43","span":{"begin":254,"end":258},"obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"T44","span":{"begin":254,"end":258},"obj":"http://www.ebi.ac.uk/efo/EFO_0000816"}],"text":"SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T5","span":{"begin":735,"end":746},"obj":"http://purl.obolibrary.org/obo/GO_0050817"}],"text":"SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment."}

{"project":"LitCovid-PubTator","denotations":[{"id":"126","span":{"begin":72,"end":92},"obj":"Disease"},{"id":"127","span":{"begin":126,"end":144},"obj":"Disease"},{"id":"128","span":{"begin":146,"end":167},"obj":"Disease"},{"id":"129","span":{"begin":168,"end":179},"obj":"Disease"},{"id":"130","span":{"begin":181,"end":198},"obj":"Disease"},{"id":"131","span":{"begin":243,"end":269},"obj":"Disease"},{"id":"132","span":{"begin":274,"end":289},"obj":"Disease"},{"id":"133","span":{"begin":569,"end":577},"obj":"Disease"},{"id":"134","span":{"begin":721,"end":746},"obj":"Disease"}],"attributes":[{"id":"A126","pred":"tao:has_database_id","subj":"126","obj":"MESH:D020246"},{"id":"A127","pred":"tao:has_database_id","subj":"127","obj":"MESH:D011655"},{"id":"A128","pred":"tao:has_database_id","subj":"128","obj":"MESH:D009203"},{"id":"A129","pred":"tao:has_database_id","subj":"129","obj":"MESH:D009205"},{"id":"A130","pred":"tao:has_database_id","subj":"130","obj":"MESH:D014715"},{"id":"A131","pred":"tao:has_database_id","subj":"131","obj":"MESH:D020246"},{"id":"A132","pred":"tao:has_database_id","subj":"132","obj":"MESH:D002544"},{"id":"A133","pred":"tao:has_database_id","subj":"133","obj":"MESH:D006470"},{"id":"A134","pred":"tao:has_database_id","subj":"134","obj":"MESH:D004211"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T17","span":{"begin":72,"end":92},"obj":"Phenotype"},{"id":"T18","span":{"begin":126,"end":144},"obj":"Phenotype"},{"id":"T19","span":{"begin":146,"end":167},"obj":"Phenotype"},{"id":"T20","span":{"begin":168,"end":179},"obj":"Phenotype"},{"id":"T21","span":{"begin":243,"end":269},"obj":"Phenotype"},{"id":"T22","span":{"begin":274,"end":289},"obj":"Phenotype"},{"id":"T23","span":{"begin":708,"end":746},"obj":"Phenotype"}],"attributes":[{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002625"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002204"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0001658"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0012819"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0030247"},{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0002140"},{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0005521"}],"text":"SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment."}

{"project":"LitCovid-sentences","denotations":[{"id":"T51","span":{"begin":0,"end":836},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment."}

{"project":"Inflammaging","denotations":[{"id":"T51","span":{"begin":0,"end":836},"obj":"Sentence"},{"id":"T51","span":{"begin":0,"end":836},"obj":"Sentence"}],"text":"SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment."}